Affimed (NASDAQ:AFMD) Receives Average Rating of “Moderate Buy” from Brokerages

Affimed (NASDAQ:AFMD) has been given a consensus rating of “Moderate Buy” by the five brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $13.50.

Several brokerages recently commented on AFMD. StockNews.com assumed coverage on Affimed in a report on Tuesday. They set a “sell” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Affimed in a research note on Tuesday, December 10th. Finally, Wells Fargo & Company decreased their target price on Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th.

Institutional Investors Weigh In On Affimed

Institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of Affimed in the 3rd quarter valued at $44,000. FMR LLC boosted its holdings in shares of Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares during the period. Intellectus Partners LLC increased its position in shares of Affimed by 34.0% in the fourth quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 32,053 shares in the last quarter. Northern Trust Corp acquired a new stake in shares of Affimed during the fourth quarter valued at approximately $218,000. Finally, Point72 Asset Management L.P. lifted its position in shares of Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares in the last quarter. 30.82% of the stock is owned by institutional investors and hedge funds.

Affimed Stock Performance

Shares of NASDAQ:AFMD opened at $0.72 on Tuesday. The firm’s 50 day moving average is $0.98 and its two-hundred day moving average is $2.06. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93. Affimed has a 52 week low of $0.72 and a 52 week high of $8.95.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.